Myriad Genetics INC Form 4 insider transactions
NASDAQ
Director Heinrich Dreismann reports acquisition of restricted stock units in Myriad Genetics, Inc.
NASDAQ
Form 4: Myriad Genetics Director Lee Nisley Newcomer Reports Acquisition and Disposal of Common Stock
Director Lee Nisley Newcomer reports acquiring and disposing of Myriad Genetics common stock, including restricted stock units, in a recent transaction.
NASDAQ
Director Rashmi Kumar reported the acquisition of 15,695 restricted stock units in Myriad Genetics, Inc.
NASDAQ
Director Colleen F. Reitan reported acquiring 15,695 shares of Myriad Genetics Inc. common stock and disposing of shares, resulting in a total beneficial ownership of 88,545 shares.
NASDAQ
Director S. Louise Phanstiel reports the acquisition of Myriad Genetics (MYGN) stock and restricted stock units.
NASDAQ
Director Paul Bisaro reports acquisition of restricted stock units and disposal of common stock.
NASDAQ
Daniel K. Spiegelman, a director at Myriad Genetics, filed a Form 4 with the SEC to report his departure from the company, effective June 6, 2024.
NASDAQ
Director Daniel K. Spiegelman of Myriad Genetics sold a portion of his common stock holdings on June 3rd and 4th, 2024, under a pre-arranged Rule 10b5-1 trading plan.
NASDAQ
Paul J. Diaz, President and CEO of Myriad Genetics, sold a significant number of shares of common stock over three days in May 2024.
NASDAQ
Director Lee Nisley Newcomer of Myriad Genetics Inc. sold 6,200 shares of common stock at an average price of $25.30 on May 13, 2024.
NASDAQ
Dale Muzzey, Chief Scientific Officer of Myriad Genetics, disposed of shares to cover tax obligations related to vesting restricted stock units.
NASDAQ
Mark Verratti, Chief Commercial Officer of Myriad Genetics, reports the withholding of 1,076 common stock shares to cover tax obligations related to vesting restricted stock units.
NASDAQ
Natalie Munk, Chief Accounting Officer of Myriad Genetics, reports the withholding of shares to cover tax obligations related to vesting restricted stock units.
NASDAQ
Scott J. Leffler, CFO of Myriad Genetics, files an amendment to correct the number of restricted stock units granted on March 14, 2024.
NASDAQ
Natalie Munk, Chief Accounting Officer of Myriad Genetics, reports the disposal of 363 common stock shares to cover tax obligations related to vesting restricted stock units on March 25, 2024.
NASDAQ
Pamela Wong, Chief Legal Officer of Myriad Genetics, disposed of shares to cover tax obligations related to vesting restricted stock units and is no longer subject to Section 16 reporting as of March 22, 2024.
NASDAQ
Natalie Munk, Chief Accounting Officer of Myriad Genetics, reports the disposal of shares to cover tax obligations related to vesting restricted stock units.
NASDAQ
Margaret Ancona, SVP and Chief of Staff at Myriad Genetics, disposed of 730 shares of common stock on March 22, 2024, to cover tax withholding obligations related to vesting restricted stock units.
NASDAQ
Kevin Richard Haas, Chief Technology Officer of Myriad Genetics, reported disposing of shares to cover tax withholding obligations related to vesting restricted stock units.
NASDAQ
Dale Muzzey, Chief Scientific Officer of Myriad Genetics, reports the withholding of shares to cover tax obligations related to vesting restricted stock units.
NASDAQ
Mark Verratti, Chief Commercial Officer of Myriad Genetics, reports disposing of shares to cover tax obligations related to vesting restricted stock units.
NASDAQ
Paul J. Diaz, President and CEO of Myriad Genetics, reports the withholding of shares to cover tax obligations related to vesting restricted stock units.
NASDAQ
Pamela Wong, Chief Legal Officer of Myriad Genetics, reports disposition of shares to cover tax obligations related to vesting restricted stock units.
NASDAQ
Natalie Munk, Chief Accounting Officer of Myriad Genetics, reports acquiring 7,500 shares of common stock as part of a restricted stock unit grant.
NASDAQ
Margaret Ancona, SVP and Chief of Staff at Myriad Genetics, reports the acquisition and disposal of company stock, including restricted stock units and shares withheld for tax obligations.
NASDAQ
Kevin Richard Haas, Chief Technology Officer of Myriad Genetics, reports acquisition of restricted stock units and disposal of shares to cover tax obligations.
NASDAQ
Shereen Solaiman, Chief People Officer at Myriad Genetics, reports the acquisition of 41,042 shares of common stock through a restricted stock unit grant.
NASDAQ
Dale Muzzey, Chief Scientific Officer of Myriad Genetics, reports acquisition of restricted stock units and subsequent disposal of shares to cover tax obligations.
NASDAQ
Mark Verratti, Chief Commercial Officer of Myriad Genetics, acquired shares through restricted stock units and disposed of shares to cover tax obligations.
NASDAQ
Chief Operating Officer of Myriad Genetics, Samraat S. Raha, reports acquiring and disposing of common stock and holding 300,854 shares following the transaction.